<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460577</url>
  </required_header>
  <id_info>
    <org_study_id>CFOR258DVE02</org_study_id>
    <nct_id>NCT00460577</nct_id>
  </id_info>
  <brief_title>Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-&lt;12 Years) With Acute Bronchial Obstruction</brief_title>
  <official_title>Randomized, Double Blind, Double Dummy, Placebo Controlled Trial to Compare the Effectiveness of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Asthmatic Children (5-&lt;12 Years) With Acute Bronchial Obstruction Attending Emergency Services</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      To determine efficacy and tolerability of inhaled Formoterol vs nebulized Ipatropioum Bromide
      plus Fenoterol in cumulative sequential doses in asthmatic children (5-&lt;12 years) with acute
      bronchial obstruction attending emergency services
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Maximum Expiratory Flow From Baseline to Final Evaluation</measure>
    <time_frame>Baseline,4 hours</time_frame>
    <description>Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Maximum Expiratory Flow.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Final Evaluation</measure>
    <time_frame>Baseline,4 hours</time_frame>
    <description>Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Forced Expiratory Volume in 1 second. FEV1 is defined as the volume of air that can be forced out of the lungs in 1 second after taking a deep breath.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Pulse Oxymetry From Baseline to Final Evaluation</measure>
    <time_frame>Baseline, 4 hours</time_frame>
    <description>Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Pulse Oximetry used to monitor the percentage of oxygen saturation of hemoglobin in the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in the Conway Clinical Scale Score From Baseline to Final Evaluation</measure>
    <time_frame>Baseline,4 hours</time_frame>
    <description>Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by the Conway Clinical Scale. Assessment of the following: Wheezing, Accessory Muscle Use and Pulse Frequency in a 0 to 3 point scale according to severity for a minimum of 0 points and a total of 9 points in a very severe clinical case.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessed by: Pulse Oxymetry, Clinical Assessments, Adverse Events</measure>
    <time_frame>4 hours</time_frame>
    <description>Not posted: see comment in Limitations and Caveats.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomic Analysis</measure>
    <time_frame>4 hours</time_frame>
    <description>Pharmacoeconomic analysis comparing the mean direct costs (total cost per prescription) of treatment with Formoterol (Foradil®) to treatment with Fenoterol 0.5 mg + Berodual®.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Acute Bronchial Obstruction, Asthma</condition>
  <arm_group>
    <arm_group_label>Formoterol (Foradil®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol fumerate</intervention_name>
    <description>12 micrograms stat (twice if necessary). Inhaled via aerolizer</description>
    <arm_group_label>Formoterol (Foradil®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenoterol/ipratropium bromide</intervention_name>
    <description>0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline.</description>
    <arm_group_label>Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asthmatic children 5-&lt;12 years old, requiring emergency services for acute bronchial
             obstruction mild to moderate determined by functional and clinical evidence

        Exclusion Criteria:

          -  Patients with severe acute bronchial obstruction determined by functional and clinical
             evidence

          -  Patients unable to use the inhaling device at time of treatment

          -  Patients who received a bronchodilator drug within the last 12 hours

          -  Patients who received inhaled steroids within the last 72 hours

          -  Patients who received systemic steroids within the last 7 days

          -  Patients with near fatal asthma history

          -  Patients with fever (&gt;38.5°C axillar temp)

          -  Patients with any clinical significance condition

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis de Venezuela</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis de Venezuela</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator site - five sites in Caracas</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Maracaibo</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Venezuela</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2007</study_first_submitted>
  <study_first_submitted_qc>April 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2007</study_first_posted>
  <results_first_submitted>December 13, 2010</results_first_submitted>
  <results_first_submitted_qc>March 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 19, 2011</results_first_posted>
  <last_update_submitted>March 23, 2011</last_update_submitted>
  <last_update_submitted_qc>March 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>External affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Asthma, Formoterol, Bronchial Obstruction, Children</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
    <mesh_term>Fenoterol</mesh_term>
    <mesh_term>Fenoterol, ipratropium drug combination</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Formoterol (Foradil®)</title>
          <description>Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.</description>
        </group>
        <group group_id="P2">
          <title>Fenoterol 0.5 mg + Berodual®</title>
          <description>Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30">148 patients were screened; however, 22 did not consent and 66 did not meet inclusion/exclusion.</participants>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Formoterol (Foradil®)</title>
          <description>Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.</description>
        </group>
        <group group_id="B2">
          <title>Fenoterol 0.5 mg + Berodual®</title>
          <description>Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.8" spread="1.5"/>
                    <measurement group_id="B2" value="7.8" spread="2.1"/>
                    <measurement group_id="B3" value="7.8" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum Inspiratory Flow</title>
          <description>Mean of the Maximum Inspiratory Flow</description>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.7" spread="16.7"/>
                    <measurement group_id="B2" value="79.9" spread="17.5"/>
                    <measurement group_id="B3" value="78.8" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum Expiratory Flow</title>
          <description>Mean of Maximum Expiratory Flow</description>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140.3" spread="33.1"/>
                    <measurement group_id="B2" value="150.3" spread="36.6"/>
                    <measurement group_id="B3" value="145.3" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced Expiratory Flow 1 sec</title>
          <description>Mean of Forced Expiratory Flow one second (FEV1) defined as the volume of air that can be forced out in 1 second after taking a deep breath.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.06" spread="0.280"/>
                    <measurement group_id="B2" value="1.12" spread="0.289"/>
                    <measurement group_id="B3" value="1.09" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced Expiratory Flow 1 sec as a Percentage of Predicted</title>
          <description>Mean Expiratory Flow 1 second as a Percentage of Predicted</description>
          <units>Percentage of Predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.05" spread="15.22"/>
                    <measurement group_id="B2" value="71.17" spread="15.76"/>
                    <measurement group_id="B3" value="69.11" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Conway Clinical Scale</title>
          <description>Mean of Clinical Scale score measured by assessment of the following: Wheezing, Accessory Muscle Use and Pulse Frequency in a 0 to 3 point scale according to severity for a minimum of 0 points and a total of 9 points in a very severe clinical case.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="1.4"/>
                    <measurement group_id="B2" value="4.0" spread="1.5"/>
                    <measurement group_id="B3" value="4.05" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Maximum Expiratory Flow From Baseline to Final Evaluation</title>
        <description>Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Maximum Expiratory Flow.</description>
        <time_frame>Baseline,4 hours</time_frame>
        <population>Per protocol population: defined as number of patients who did not present any major deviations from protocol and received at least one dose of investigational study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol (Foradil®)</title>
            <description>Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.</description>
          </group>
          <group group_id="O2">
            <title>Fenoterol 0.5 mg + Berodual®</title>
            <description>Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Maximum Expiratory Flow From Baseline to Final Evaluation</title>
          <description>Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Maximum Expiratory Flow.</description>
          <population>Per protocol population: defined as number of patients who did not present any major deviations from protocol and received at least one dose of investigational study drug.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" spread="26.87"/>
                    <measurement group_id="O2" value="43.67" spread="20.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Assessed by: Pulse Oxymetry, Clinical Assessments, Adverse Events</title>
        <description>Not posted: see comment in Limitations and Caveats.</description>
        <time_frame>4 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacoeconomic Analysis</title>
        <description>Pharmacoeconomic analysis comparing the mean direct costs (total cost per prescription) of treatment with Formoterol (Foradil®) to treatment with Fenoterol 0.5 mg + Berodual®.</description>
        <time_frame>4 hours</time_frame>
        <population>Per protocol population: defined as number of patients who did not present any major deviations from protocol and received at least one dose of investigational study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol (Foradil®)</title>
            <description>Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.</description>
          </group>
          <group group_id="O2">
            <title>Fenoterol 0.5 mg + Berodual®</title>
            <description>Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacoeconomic Analysis</title>
          <description>Pharmacoeconomic analysis comparing the mean direct costs (total cost per prescription) of treatment with Formoterol (Foradil®) to treatment with Fenoterol 0.5 mg + Berodual®.</description>
          <population>Per protocol population: defined as number of patients who did not present any major deviations from protocol and received at least one dose of investigational study drug.</population>
          <units>Cost in US Dollars</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.21" lower_limit="6.19" upper_limit="12.93"/>
                    <measurement group_id="O2" value="25.67" lower_limit="21.95" upper_limit="29.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Final Evaluation</title>
        <description>Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Forced Expiratory Volume in 1 second. FEV1 is defined as the volume of air that can be forced out of the lungs in 1 second after taking a deep breath.</description>
        <time_frame>Baseline,4 hours</time_frame>
        <population>Per protocol population: defined as number of patients who did not present any major deviations from protocol and received at least one dose of investigational study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol (Foradil®)</title>
            <description>Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.</description>
          </group>
          <group group_id="O2">
            <title>Fenoterol 0.5 mg + Berodual®</title>
            <description>Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Final Evaluation</title>
          <description>Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Forced Expiratory Volume in 1 second. FEV1 is defined as the volume of air that can be forced out of the lungs in 1 second after taking a deep breath.</description>
          <population>Per protocol population: defined as number of patients who did not present any major deviations from protocol and received at least one dose of investigational study drug.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.2"/>
                    <measurement group_id="O2" value="0.34" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Pulse Oxymetry From Baseline to Final Evaluation</title>
        <description>Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Pulse Oximetry used to monitor the percentage of oxygen saturation of hemoglobin in the blood.</description>
        <time_frame>Baseline, 4 hours</time_frame>
        <population>Per protocol population: defined as number of patients who did not present any major deviations from protocol and received at least one dose of investigational study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol (Foradil®)</title>
            <description>Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.</description>
          </group>
          <group group_id="O2">
            <title>Fenoterol 0.5 mg + Berodual®</title>
            <description>Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Pulse Oxymetry From Baseline to Final Evaluation</title>
          <description>Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Pulse Oximetry used to monitor the percentage of oxygen saturation of hemoglobin in the blood.</description>
          <population>Per protocol population: defined as number of patients who did not present any major deviations from protocol and received at least one dose of investigational study drug.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="1.67"/>
                    <measurement group_id="O2" value="2.83" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in the Conway Clinical Scale Score From Baseline to Final Evaluation</title>
        <description>Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by the Conway Clinical Scale. Assessment of the following: Wheezing, Accessory Muscle Use and Pulse Frequency in a 0 to 3 point scale according to severity for a minimum of 0 points and a total of 9 points in a very severe clinical case.</description>
        <time_frame>Baseline,4 hours</time_frame>
        <population>Per protocol population: defined as number of patients who did not present any major deviations from protocol and received at least one dose of investigational study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol (Foradil®)</title>
            <description>Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.</description>
          </group>
          <group group_id="O2">
            <title>Fenoterol 0.5 mg + Berodual®</title>
            <description>Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in the Conway Clinical Scale Score From Baseline to Final Evaluation</title>
          <description>Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by the Conway Clinical Scale. Assessment of the following: Wheezing, Accessory Muscle Use and Pulse Frequency in a 0 to 3 point scale according to severity for a minimum of 0 points and a total of 9 points in a very severe clinical case.</description>
          <population>Per protocol population: defined as number of patients who did not present any major deviations from protocol and received at least one dose of investigational study drug.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.18" spread="1.59"/>
                    <measurement group_id="O2" value="-3.04" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Formoterol (Foradil®)</title>
          <description>Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.</description>
        </group>
        <group group_id="E2">
          <title>Fenoterol 0.5 mg + Berodual®</title>
          <description>Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Secondary Outcome Measure 2: Safety Assessed by Pulse Oxymetry, Clinical Assessments, Adverse Events has not been posted. Analysis of Pulse Oxymetry and Clinical Assessment was not performed. Adverse events are reported in the Adverse Event section.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

